Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 8/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29137167 | 0.72 | DNM1 (0.50) | DNM1CA12CA1CA2CA9 | |
| SCHEMBL29137157 | 0.72 | DNM1 (0.50) | DNM1CA12CA1CA2CA9 | |
| SCHEMBL29137180 | 0.72 | DNM1 (0.50) | DNM1CA12CA1CA2CA9 | |
| SCHEMBL29137123 | 0.72 | DNM1 (0.50) | DNM1CA12CA1CA2CA9 | |
| SCHEMBL29137155 | 0.72 | — | — | |
| SCHEMBL28490075 | 0.72 | DNM1 (0.50) | DNM1CA12CA1CA2CA9 | |
| SCHEMBL10758036 | 0.71 | DNM1 (0.55) | DNM1CA12CA1CA2CA9 | |
| SCHEMBL1793039 | 0.71 | DNM1 (0.55) | DNM1CA12CA1CA2CA9 | |
| SCHEMBL11179206 | 0.71 | DNM1 (0.55) | DNM1CA12CA1CA2CA9 | |
| SCHEMBL7756737 | 0.71 | DNM1 (0.55) | DNM1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290531-B2 | Synthetic LTA mimetics and use thereof as vaccine component for therapy and/or prophylaxis against gram-positive infections | Universitätsklinikum Freiburg (DE) | 2016-03-22 | — | — | US | disclosed |
| EP-2500349-B1 | Synthetic LTA mimetics and use thereof as vaccine component for therapy and/or prophylaxis against gram-positive infections | Universitätsklinikum Freiburg (DE) | 2015-05-06 | — | — | EP | disclosed |
| US-20140050741-A1 | SYNTHETIC LTA MIMETICS AND USE THEREOF AS VACCINE COMPONENT FOR THERAPY AND/OR PROPHYLAXIS AGAINST GRAM-POSITIVE INFECTIONS | UNIVERSITEIT LEIDEN (NL) | 2014-02-20 | — | — | US | disclosed |
| EP-2500349-A1 | Synthetic LTA mimetics and use thereof as vaccine component for therapy and/or prophylaxis against gram-positive infections | Universitätsklinikum Freiburg (DE) | 2012-09-19 | — | — | EP | disclosed |
| WO-2012119846-A1 | SYNTHETIC LTA MIMETICS AND USE THEREOF AS VACCINE COMPONENT FOR THERAPY AND/OR PRO-PHYLAXIS AGAINST GRAM-POSITIVE INFECTIONS | Universitätsklinikum Freiburg (DE) | 2012-09-13 | — | — | WO | disclosed |
| US-6348596-B1 | NUCLEIC ACID HYBRIDIZATION ASSAYS; DNA SEQUENCE DETERMINATION | PE CORPORATION (NY) | 2002-02-19 | — | — | US | disclosed |
| EP-0840741-A1 | PNA-DNA CHIMERAS AND PNA SYNTHONS FOR THEIR PREPARATION | PERSEPTIVE BIOSYSTEMS, INC. (US) | 1998-05-13 | — | — | EP | disclosed |
| WO-1996040709-A1 | PNA-DNA CHIMERAS AND PNA SYNTHONS FOR THEIR PREPARATION | PERSEPTIVE BIOSYSTEMS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140050741-A1 | SYNTHETIC LTA MIMETICS AND USE THEREOF AS VACCINE COMPONENT FOR THERAPY AND/OR PROPHYLAXIS AGAINST GRAM-POSITIVE INFECTIONS | LTA, LTN1, LTC4S | DNM1 2372/4885CA12 3008/4885CA1 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.